Javascript must be enabled to continue!
Liver Transplantation in Patients with Alcoholic Liver Disease
View through CrossRef
Although alcoholic liver disease (ALD) is one of the most common indications for liver transplantation (LT), there are still unresolved controversies about the goals of treatment, the referral, evaluation, and selection of patients with ALD for LT, and their care after LT. It is uncertain whether there is a large unmet need for LT among patients with ALD because of the unmeasured effects of recent drinking, relapse, and recovery with abstinence in this population. A careful assessment of the extrahepatic effects of alcohol-related end-organ damage is needed for ALD patients who are referred for an LT evaluation. Although there clearly is a relationship between the length of sobriety and future abstinence, the present methods for predicting future drinking are inexact. The survival of ALD patients after LT is as good as the survival of non-ALD patients, although patients with coincident ALD and hepatitis C virus have higher mortality and morbidity rates. After LT, ALD patients have an increased risk of developing malignancies and cardiovascular disease. These risks appear to be linked to cigarette smoking. Covert drinking occurs both before and after transplantation, and approximately 20% of patients return to harmful drinking after LT. Harmful drinking after LT (instead of slips) causes liver damage and reduces survival. Better therapies for controlling addictions to alcohol and nicotine are needed for ALD patients both before and after LT. Liver Transpl 17:751-759, 2011. © 2011 AASLD.
Title: Liver Transplantation in Patients with Alcoholic Liver Disease
Description:
Although alcoholic liver disease (ALD) is one of the most common indications for liver transplantation (LT), there are still unresolved controversies about the goals of treatment, the referral, evaluation, and selection of patients with ALD for LT, and their care after LT.
It is uncertain whether there is a large unmet need for LT among patients with ALD because of the unmeasured effects of recent drinking, relapse, and recovery with abstinence in this population.
A careful assessment of the extrahepatic effects of alcohol-related end-organ damage is needed for ALD patients who are referred for an LT evaluation.
Although there clearly is a relationship between the length of sobriety and future abstinence, the present methods for predicting future drinking are inexact.
The survival of ALD patients after LT is as good as the survival of non-ALD patients, although patients with coincident ALD and hepatitis C virus have higher mortality and morbidity rates.
After LT, ALD patients have an increased risk of developing malignancies and cardiovascular disease.
These risks appear to be linked to cigarette smoking.
Covert drinking occurs both before and after transplantation, and approximately 20% of patients return to harmful drinking after LT.
Harmful drinking after LT (instead of slips) causes liver damage and reduces survival.
Better therapies for controlling addictions to alcohol and nicotine are needed for ALD patients both before and after LT.
Liver Transpl 17:751-759, 2011.
© 2011 AASLD.
Related Results
[RETRACTED] Bridport Health Reviews - Powerfully Detoxifies The Liver, Lose Liver Fat And Improve Gut Health! v1
[RETRACTED] Bridport Health Reviews - Powerfully Detoxifies The Liver, Lose Liver Fat And Improve Gut Health! v1
[RETRACTED]Product Name - Bridport Health Ingredients - Milk Thistle, Beetroot, Artichoke Extract & More. Category - Liver Support Supplement Main Benefits - Helps Protect The ...
[RETRACTED] Bridport Health Liver Support Does It Really Work v1
[RETRACTED] Bridport Health Liver Support Does It Really Work v1
[RETRACTED]Depiction • Where to Get Bottle Online –Click Here • Item Name -Bridport Health Liver • Aftereffects - No Major Side Effects • Classification - Health • Accessibility -O...
Reduction of the Recipient Spleen Size After Living Donor Liver Transplantation A Retrospective Study.
Reduction of the Recipient Spleen Size After Living Donor Liver Transplantation A Retrospective Study.
Abstract
Background: Liver transplantation is considered an important solution to patients with end stage liver disease and a glimpse of hope for some patients with terribl...
Reduction of Recipient Spleen Size after Living Donor Liver Transplantation: A Retrospective Study
Reduction of Recipient Spleen Size after Living Donor Liver Transplantation: A Retrospective Study
Abstract
Background
Liver transplantation is considered an important solution to patients with end stage liver disease and a gli...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Rethinking Anticoagulation in Kidney Disease and Kidney Transplantation
Rethinking Anticoagulation in Kidney Disease and Kidney Transplantation
BackgroundA clinical dilemma exists in patients with CKD, ESKD, and after kidney transplantation, as they face concurrent risks of both thromboembolic and hemorrhagic complications...
Hepatoprotective activity of Ammi majus on CCL4 Induced Albino Mice
Hepatoprotective activity of Ammi majus on CCL4 Induced Albino Mice
This study was amid to evaluate the possible protective effects of the water and alcoholic extract of Ammi majus seeds against liver damage induced in mice by CCL4. The plant was c...
10-YEAR RISK OF CVD IN PATIENTS WITH METABOLIC SYNDROME WITH AND WITHOUT NAFLD
10-YEAR RISK OF CVD IN PATIENTS WITH METABOLIC SYNDROME WITH AND WITHOUT NAFLD
Background: Metabolic syndrome is a major cardiometabolic disorder that increases the likelihood of future cardiovascular disease through clustered abnormalities such as central ob...

